文献速递胸部肿瘤

Prolgolimab联合化疗一线治疗晚期非鳞状非小细胞肺癌

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
PubMed 文献 · Eur J Cancer · 2025-01-21

III期DOMAJOR研究将292例晚期非鳞状非小细胞肺癌患者按1:1随机分配至Prolgolimab联合培美曲塞及铂类药物组或安慰剂联合培美曲塞及铂类药物组。中位随访18个月后,Prolgolimab联合组中位总生存期未达到(95%CI 22.28-NA),安慰剂联合组为14.6个月(95%CI 11.73-19.15),风险比(HR)0.51(95%CI 0.35-0.73,p=0.0001)。总生存期获益独立于PD-L1状态,中位无进展生存期(PFS)分别为7.7个月和5.5个月(HR 0.65,95%CI 0.49-0.85,p=0.0004)。

要点

  • Prolgolimab联合培美曲塞及铂类一线治疗晚期非鳞状非小细胞肺癌,中位总生存期未达到 vs 安慰剂联合组14.6个月(HR 0.51,95%CI 0.35-0.73,p=0.0001)。
  • 中位无进展生存期(RECIST 1.1)Prolgolimab联合组7.7个月 vs 安慰剂联合组5.5个月(HR 0.65,95%CI 0.49-0.85,p=0.0004)。
  • 总生存期获益独立于PD-L1状态,在PD-L1阴性肿瘤患者中该获益得以保留。

核心结论

  • 在晚期非小细胞肺癌患者中,Prolgolimab联合培美曲塞及铂类药物较安慰剂联合培美曲塞及铂类药物提高了总生存期和无进展生存期,未观察到新的安全性问题,且该获益在PD-L1阴性肿瘤患者中得以保留。

研究设计与样本

  • III期DOMAJOR研究,292例晚期非鳞状非小细胞肺癌患者按1:1随机分配至Prolgolimab联合培美曲塞及铂类药物组或安慰剂联合培美曲塞及铂类药物组。
  • 患者接受4个周期培美曲塞、铂类药物及Prolgolimab(3 mg/kg 每3周一次)或安慰剂,随后继续Prolgolimab或安慰剂联合培美曲塞直至疾病进展或毒性(≤36个月)。
  • 主要终点为总生存期,中位随访18个月。

主要发现

  • Prolgolimab联合组中位总生存期未达到(95%CI 22.28-NA),安慰剂联合组为14.6个月(95%CI 11.73-19.15),HR 0.51(95%CI 0.35-0.73),p=0.0001。
  • 总生存期改善独立于PD-L1状态。
  • Prolgolimab联合组中位无进展生存期(RECIST 1.1)为7.7个月,安慰剂联合组为5.5个月,HR 0.65(95%CI 0.49-0.85),p=0.0004。
  • 在至少10%患者中报告且Prolgolimab联合组显著更频繁的不良事件仅为血肌酐升高和呼吸困难。

关键数值与推荐

  • Prolgolimab为IgG1抗PD-1单克隆抗体,带有Fc沉默LALA突变。
  • Prolgolimab剂量为3 mg/kg 每3周一次,联合培美曲塞及铂类药物,共4个周期,随后Prolgolimab联合培美曲塞维持治疗直至疾病进展或毒性(≤36个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing 'LALA' mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). METHODS: 292 patients with advanced non-squamous NSCLC were randomized 1:1 to receive 4 cycles of pemetrexed, platinum-based drug and either prolgolimab (3 mg/kg Q3W) or placebo followed by prolgolimab/placebo with pemetrexed until disease progression or toxicity (≤36 months). The primary endpoint was overall survival (OS). RESULTS: After a median follow-up of 18 months, the median OS was not reached (95 % CI, 22.28 - NA) in the prolgolimab-combination group vs 14.6 months (95 % CI, 11.73 - 19.15) in the placebo-combination group (HR, 0.51; 95 % CI, 0.35 - 0.73, p = 0.0001). The OS improvement was independent of PD-L1 status. Median progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was 7.7 months in the prolgolimab-combination group and 5.5 months in the placebo-combination group (HR, 0.65; 95 % CI, 0.49 - 0.85, p = 0.0004). The only adverse events that were reported in at least 10 % of the patients that were significantly more frequent in the prolgolimab-combination group were blood creatinine increased and dyspnoea. CONCLUSION: Among patients with advanced NSCLC the addition of prolgolimab to pemetrexed and a platinum-based drug increased OS and PFS, with no new safety concerns. This benefit was retained in patients with PD-L1 negative tumors. (ClinicalTrials.gov, NCT03912389).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Laktionov K, Smolin A, Stroyakovskiy D, et al. Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer. Eur J Cancer. 2025. PMID: 39879779. doi:10.1016/j.ejca.2025.115255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。